Recruitment is one the most important parts of a clinical trial, but when literature is reviewed it seems that not reaching initial recruitment targets within initial timelines is more the rule than the exception. This indicates that current recruitment strategies are shortcoming and need to be reviewed.
This Applied Clinical Trials article describes an online, cross-sectional survey in Belgium that was conducted to systematically assess the opinions of clinical research professionals from different stakeholders about using social media as a targeting recruitment tool.
Click here for more.
Social Media and Clinical Trial Recruitment
Pharmaceutical Executive
A review of an online, cross-sectional survey in Belgium that was conducted to systematically assess the opinions of clinical research professionals from different stakeholders about using social media as a targeting recruitment tool.
Recruitment is one the most important parts of a clinical trial, but when literature is reviewed it seems that not reaching initial recruitment targets within initial timelines is more the rule than the exception. This indicates that current recruitment strategies are shortcoming and need to be reviewed.
This Applied Clinical Trials article describes an online, cross-sectional survey in Belgium that was conducted to systematically assess the opinions of clinical research professionals from different stakeholders about using social media as a targeting recruitment tool.
Click here for more.
Nipocalimab Demonstrates Sustained Disease Control in Adolescents with Generalized Myasthenia Gravis
Results from the Phase II/III Vibrance-MG study found that patients with generalized myasthenia gravis who were treated with nipocalimab plus standard-of-care achieved sustained disease control.
Cell and Gene Therapy Check-in 2024
Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
How to Rally a Team Around Building a New Business
Three key components to scaling quickly—while maintaining purpose.
Arexvy Demonstrates Sustained Protection From Respiratory Syncytial Virus in Adults Over 60 Years of Age for Three Seasons
Data from the Phase III AReSVi-006 clinical trial found that Arexvy offered a cumulative efficacy of 62.9% against lower respiratory tract disease caused by respiratory syncytial virus.
Diseases of Aging: Q&A with Dr. Thomas Ichim
Immorta Bio’s president discusses the company’s work with age-related diseases.
Johnson & Johnson Expands Rollout of TECNIS Odyssey for Correcting Presbyopia
Designed for cataract patients, the TECNIS Odyssey aims to reduce the need for glasses by offering a full range of precise vision at all distances.
Nipocalimab Demonstrates Sustained Disease Control in Adolescents with Generalized Myasthenia Gravis
Results from the Phase II/III Vibrance-MG study found that patients with generalized myasthenia gravis who were treated with nipocalimab plus standard-of-care achieved sustained disease control.
Cell and Gene Therapy Check-in 2024
Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
How to Rally a Team Around Building a New Business
Three key components to scaling quickly—while maintaining purpose.
Arexvy Demonstrates Sustained Protection From Respiratory Syncytial Virus in Adults Over 60 Years of Age for Three Seasons
Data from the Phase III AReSVi-006 clinical trial found that Arexvy offered a cumulative efficacy of 62.9% against lower respiratory tract disease caused by respiratory syncytial virus.
Diseases of Aging: Q&A with Dr. Thomas Ichim
Immorta Bio’s president discusses the company’s work with age-related diseases.
Johnson & Johnson Expands Rollout of TECNIS Odyssey for Correcting Presbyopia
Designed for cataract patients, the TECNIS Odyssey aims to reduce the need for glasses by offering a full range of precise vision at all distances.